Benzinga
28 Nov 2025, 15:13 UTC · 46w ago
Verdict
Headline leans bearish. We score ASND −0.30 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.30moderately bearish
More negative than 67% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA has extended the PDUFA target action date for TransCon CNP by three months to February 28, 2026, following a major amendment to the NDA.
More negative than 94% of claims this week
TransCon PTH Phase 2 and 3 trial data showed that over 84% of patients achieved normocalcemia and 70.3% saw improvements in eGFR through year 3.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 80% of claims this week
Pivotal week 52 results from the ApproaCH Trial of TransCon CNP in children with achondroplasia have been published in JAMA Pediatrics.
More positive than 56% of claims this week
Which stocks this story touches
More negative than 67% of ticker scores this week
The company's TransCon CNP decision was delayed by the FDA until February 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
23h ago
+13.8%
Price is moving against the score
$238.90 vs $210.01 close before publication (Nov 26) · not market-adjusted
ASND chart →
